Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Business Wire•06/10/2026•08:00 ET
0
Key Highlights
- ➤Amylyx (AMLX) will present Phase 3 LUCIDITY topline data at ObesityWeek 2026
- ➤LUCIDITY evaluated avexitide in 78 participants with post-bariatric hypoglycemia
- ➤Avexitide showed highly statistically significant hypoglycemic-event reductions in Phase 2 and Phase 3 trials
- ➤FDA granted avexitide Breakthrough Therapy Designation for PBH and congenital hyperinsulinism
- ➤PBH affects approximately 8% of U.S. patients undergoing common bariatric surgeries
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek(®) 2026 Annual Meeting
* Late-breaking oral presentation to feature Phase 3 topline data highlighting avexitide’s efficacy and safety
Get started
Create a free account to read the full story.